ReviewJournal of the National Comprehensive Cancer Network : JNCCN2012
Novel therapies in phase II and III trials for malignant pleural mesothelioma.
Review in Journal of the National Comprehensive Cancer Network : JNCCN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.Journal of the National Comprehensive Cancer Network : JNCCN · 2016Guideline
- A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors.Investigational new drugs · 2019Trial
- The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma.BMC cancer · 2015Trial
- Novel immunotherapy clinical trials in malignant pleural mesothelioma.Annals of translational medicine · 2017Article
- Succinimide Formation from an NGR-Containing Cyclic Peptide: Computational Evidence for Catalytic Roles of Phosphate Buffer and the Arginine Side Chain.International journal of molecular sciences · 2017Article
- Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease.Cell death and differentiation · 2016Article
- Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.Oncotarget · 2015Article
- Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma.Scientific reports · 2014Article
- New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.The American journal of pathology · 2013Review
- Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.Clinics in chest medicine · 2013Review
- New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Mesothelioma is a rare malignancy of the pleura with limited therapeutic options. Despite the desperate need to develop better treatment for this disease, the rarity of the tumor type creates formidable challenges in clinical research. Nonetheless, several novel agents are under investigation. Most efforts are directed toward improving standard first-line therapy with pemetrexed and cisplatin, or developing effective second-line treatments. Several classes of drugs are being explored, including those that impact DNA transcription, cell-cycle progression, angiogenesis, and immune tolerance. This article describes several ongoing or recently completed phase II and III trials using novel agents vorinostat, everolimus, CBP501, MORAb-009, NGR-hTNF, WT1 vaccine, bevacizumab, cediranib, and thalidomide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.